Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

BMS acquires diabetes player Amylin for $6.8bn

Executive Summary

After months of speculation that that it was up for sale and being pursued by multiple Big Pharma companies, publicly traded diabetes drug developer Amylin Pharmaceuticals Inc. announced it will be acquired by Bristol-Myers Squibb Co. for $6.8bn, consisting of $5.1bn in equity (based on 164mm outstanding Amylin shares) plus $1.7bn in combined Amylin net debt and a contractual payment that Amylin owes to Eli Lilly & Co. The $31-per-share cash price represents a 99% premium to the ten-day average leading up to late March 2012 reports that BMS had made a takeover bid.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Cash

Related Companies